Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures

(2015) Rajesh Shigdel et al.   BONE

Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures

(2015) L. A. Ahmed et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

(2014) Kenneth ES Poole et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images

(2013) R. Zebaze et al.   BONE

Anti-resorptive agents reduce the size of resorption cavities: A three-dimensional dynamic bone histomorphometry study

(2013) J.B. Matheny et al.   BONE

Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

(2013) Harry K. Genant et al.   BONE

Differing effects of denosumab and alendronate on cortical and trabecular bone

(2013) Roger M. Zebaze et al.   BONE

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

(2013) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis

(2012) Michael R. McClung et al.   JOURNAL OF CLINICAL DENSITOMETRY

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

(2012) David L. Lacey et al.   NATURE REVIEWS DRUG DISCOVERY

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

(2011) Paul J. Kostenuik et al.   BONE

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover

(2010) Andrew J Burghardt et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study

(2010) Roger MD Zebaze et al.   LANCET

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans

(2008) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH